Hi Lara.

> Thanks Mark for your quick answer (this has always amused me, you
> always answer so quick...nice)

And getting slower and slower every day :)

> so, just some reflexions:
>
> 1.Because FIRMA is an outlier method, wouldn't it be good to combine
> this information with the detection of DE exons and genes in order to
> detect alternative splicing events (between conditions)?. This is what
> I will do in trying to identify splicing events, with the help of
> GenomeGraphs...

I'd be interested to hear what you come up with, but some of this is done
implicitly in FIRMA(Gene).

> 2.It's amazing how variable are genes (even probesets or PSRs) in
> different when you look at a probe level (the same gene for the same
> sample can have an expression of 2 and 12), so i guess the biology
> underneath is much more complicated than our simplifications...

I think these are just probe-specific effects, which is the main reason
for fitting a model like RMA that builds in probe effects.  For example,
one of the biggest determinants of raw intensity is the number of Gs/Cs in
the probe.  There is some biology on top, of course.

Mark



>
> Cheers,
>
> Lara
>
>
> On 14 Maig, 04:37, Mark Robinson <[email protected]> wrote:
>> Hi Lara.
>>
>> Some comments below.
>>
>> On 2010-05-14, at 12:48 AM, Lara wrote:
>>
>>
>>
>> > Dear all,
>>
>> > first of all congratulations for aroma, I've been using it for a while
>> > and it saved me for the first analysis of exon arrays back in 2008.
>> > Since then I have used several times for serveral purposes.
>> > Unfortunately, sometimes there is a lack of help but a good forum...
>>
>> > So, I have been "struggling" with alternative splicing, trying to
>> > understand, and done several tests.
>> > I have performed Firma scores and limma to see differences between two
>> > groups.
>> > I have also performed DE exons (probesets) with limma.
>> > Then, I used GenomeGraphs to visualize results and I have serveral
>> > questions which i hope to write clearly and not to be obvious:
>> > 1. what I expect is, in those exons that have differences in fs, to
>> > have a clear graphical difference in expression in the selected exon
>> > between conditions but is not what I get.
>> > So, for instance, if we take 7922737 -- ENSG00000157060 -- C1orf14 --
>> > blue=Testis, which is the first example  of supplementary material (1)
>> > of "Differential splicing using whole-transcript microarrays", BMC
>> > Bioinformatics, 2009, 10,
>> 156.http://www.biomedcentral.com/content/supplementary/1471-2105-10-156-s....
>> > I know that is FIRMAGene for gene arrays, but is something similar to
>> > what I get with FIRMA and exon arrays. I would say (from the
>> > residuals) that last two exons (10 probesets) are spliced. But if you
>> > check  the expression of those probesets i wouldn't say that they have
>> > differences. On the contrary, first exons for instance seem to be
>> > spliced.
>> > Apparently, DE exons look better on graphs (no matter if they belong
>> > to a DE gene or not)
>>
>> Yes, this can happen. And, that is the real value of the GenomeGraphs
>> output.  Remember that FIRMA and FIRMAGene are really just outlier
>> detection procedures.
>>
>> This is (sort of) eluded to in both the FIRMA and FIRMAGene papers:
>>
>> Purdom et al., Section 4.1: "In particular, if the proportion of samples
>> showing alternative splicing is high within an exon (say in the majority
>> of samples), the high residuals will be found not in those samples
>> classified by the simulation as spliced out, but rather the
>> complementary set of samples"
>>
>> Robinson and Speed, Conclusions and Discusion: "Identifying departures
>> through residuals from the RMA model will not always be perfect. Some
>> departures from the RMA linear model may not be alternative splicing at
>> all ... or are induced through, for example, an exon that is not
>> expressed in any of the samples in combination with strong differential
>> expression."
>>
>> > 2. Do Firma scores correspond to residuals of rma model? because this
>> > is what you plot in genomeGraphs, isn't it?
>>
>> A FIRMA score for each sample and probeset is the median of the (usually
>> 4) residuals from the robustly-fit linear model of RMA.  See the paper
>> for the formal definition.  FIRMAGene is a little bit different, in that
>> it takes partial sums of adjacent residuals to try and look for a
>> persistence of departure from the model.
>>
>> > 3. Everything is done on a probeset basis, but shouldn't it be done on
>> > a real "exon" (exon cluster) basis?. Sometimes just a probeset appears
>> > to be "spliced" and is complicated when you try to interpret this
>> > biologically...
>>
>> Debatable.  Affymetrix picked probesets (or "probe selection regions")
>> based on what they thought could be independent units of expression,
>> based on annotated transcripts, ESTs, etc.  But, you could certainly
>> build a CDF file that grouped the probes together in a different way.
>>
>> Hope that helps.
>>
>> Cheers,
>> Mark
>>
>> > I think there is no point on adding my code and sessionInfo() given
>> > that those are "general" questions, but if you need it I can add it.
>>
>> > Thanks for your time and answer,
>>
>> > Lara
>>
>> > --
>> > When reporting problems on aroma.affymetrix, make sure 1) to run the
>> latest version of the package, 2) to report the output of
>> sessionInfo() and traceback(), and 3) to post a complete code example.
>>
>> > You received this message because you are subscribed to the Google
>> Groups "aroma.affymetrix" group with
>> websitehttp://www.aroma-project.org/.
>> > To post to this group, send email to [email protected]
>> > To unsubscribe and other options, go
>> tohttp://www.aroma-project.org/forum/
>>
>> ------------------------------
>> Mark Robinson, PhD (Melb)
>> Epigenetics Laboratory, Garvan
>> Bioinformatics Division, WEHI
>> e: [email protected]
>> e: [email protected]
>> p: +61 (0)3 9345 2628
>> f: +61 (0)3 9347 0852
>> ------------------------------
>>
>> ______________________________________________________________________
>> The information in this email is confidential and intended solely for
>> the addressee.
>> You must not disclose, forward, print or use it without the permission
>> of the sender.
>> ______________________________________________________________________
>>
>> --
>> When reporting problems on aroma.affymetrix, make sure 1) to run the
>> latest version of the package, 2) to report the output of sessionInfo()
>> and traceback(), and 3) to post a complete code example.
>>
>> You received this message because you are subscribed to the Google
>> Groups "aroma.affymetrix" group with
>> websitehttp://www.aroma-project.org/.
>> To post to this group, send email to [email protected]
>> To unsubscribe and other options, go
>> tohttp://www.aroma-project.org/forum/
>
> --
> When reporting problems on aroma.affymetrix, make sure 1) to run the
> latest version of the package, 2) to report the output of sessionInfo()
> and traceback(), and 3) to post a complete code example.
>
>
> You received this message because you are subscribed to the Google Groups
> "aroma.affymetrix" group with website http://www.aroma-project.org/.
> To post to this group, send email to [email protected]
> To unsubscribe and other options, go to
> http://www.aroma-project.org/forum/
>



______________________________________________________________________
The information in this email is confidential and intended solely for the 
addressee.
You must not disclose, forward, print or use it without the permission of the 
sender.
______________________________________________________________________

-- 
When reporting problems on aroma.affymetrix, make sure 1) to run the latest 
version of the package, 2) to report the output of sessionInfo() and 
traceback(), and 3) to post a complete code example.


You received this message because you are subscribed to the Google Groups 
"aroma.affymetrix" group with website http://www.aroma-project.org/.
To post to this group, send email to [email protected]
To unsubscribe and other options, go to http://www.aroma-project.org/forum/

Reply via email to